Loading
A phase 2/3 trial in lung cancer, run by University of Sao Paulo, active but no longer recruiting.
Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas is a phase 2/3, interventional study registered as NCT06872541 by University of Sao Paulo, with a registry enrolment figure of 100 participants, started 2025-01-20 and due to reach its primary completion in 2026-10-20. Interventions recorded: Clopidogrel. Conditions listed: Assessment of Platelet Aggregability in Patients Patients with Non-small Cell Lung Carcinoma. Primary outcome: Platelet Aggregation analyzed by optical aggregometry-ADP (AggRAM™- Helena Laboratories). Lung eligibility wording from the registry: "* Confirmed diagnosis of non-small cell lung carcinoma in the case group; absence of history of any neoplasia for control group". Sites: Brazil. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.